eJNJ

The requested name "eJNJ" most likely refers to Johnson & Johnson, but it is not the company’s exact canonical name. Johnson & Johnson is a large, active public healthcare company focused on Innovative Medicine and MedTech, with commercial products across oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision. Its Innovative Medicine business maintains a broad late-stage pipeline spanning small molecules, antibodies, bispecifics, CAR-T therapies, gene therapies, radiopharmaceuticals, and device-enabled drug delivery systems. The company markets major medicines such as Darzalex, Rybrevant, Tremfya, Carvykti, Tecvayli, Talvey, Erleada, Akeega, and Imaavy, while also advancing novel assets including icotrokinra, milvexian, bleximenib, and multiple trispecific or targeted oncology programs. Beyond therapeutics, Johnson & Johnson operates a substantial MedTech franchise with products in cardiovascular intervention, surgery, orthopaedics, and vision. For a biotech analyst, this is best understood as a diversified global healthcare leader rather than a pure-play biotech.